계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
King Star Capital
About
King Star Capital is a U.S. dollar fund managed by Kington Capital.
Highlights
Details
- Industries
- Venture Capital
- Operating Status
- Active
- Investor Type
- Venture Capital
King Star Capital is a U.S. dollar fund managed by Kington Capital. The first phase of the fund focuses on innovative biopharmaceutical companies in China. It has invested in leading anti-tumor biopharmaceutical R&D enterprises including CStone Pharmaceuticals, MabSpace Biosciences, JW Therapeutics and Adagene Pharmaceutical.
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Oct 28, 2020
Gracell Biotechnologies
|
Series C | $100M | Biotechnology | — |
|
Feb 25, 2019
Gracell Biotechnologies
|
Series B | $85M | Biotechnology | — |
|
May 11, 2018
MabSpace Biosciences
|
Series B | $40M | Biotechnology | — |
|
May 9, 2018
CStone Pharmaceuticals
|
Series B | $260M | Biotechnology | — |
|
Mar 27, 2018
Adagene
|
Series C | $50M | Biotechnology | — |
Exits
King Star Capital has had 4 exits. King Star Capital most notable exits include Adagene , Gracell Biotechnologies
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Feb 9, 2021 | Adagene | IPO | Biotechnology | Detail |
| Jan 8, 2021 | Gracell Biotechnologies | IPO | Biotechnology | Detail |
| Feb 25, 2019 | CStone Pharmaceuticals | IPO | Biotechnology | Detail |
| Jan 2, 2019 | MabSpace Biosciences | M&A | Biotechnology | Detail |
